INOVIO Seeks European Approval for HPV-Related Therapy

INOVIO Pharmaceuticals

PLYMOUTH MEETING, PA — INOVIO Pharmaceuticals (NASDAQ: INO) has applied for conditional marketing authorization in Europe for VOCERYQ, its recently approved DNA-based immunotherapy for recurrent respiratory papillomatosis, seeking to expand the treatment’s commercial reach beyond the United States as the company prepares for its first domestic launch in early 2027.

The application to the European Medicines Agency seeks approval to treat adults with recurrent respiratory papillomatosis, or RRP, a rare disease caused primarily by human papillomavirus types 6 and 11 that produces recurring growths in the respiratory tract.

The submission follows the U.S. Food and Drug Administration’s October 30, 2026, accelerated approval of VOCERYQ, making it the first plasmid DNA-based immunotherapy approved by the agency.

INOVIO is pursuing European authorization in a market where, according to the company, no approved nonsurgical treatment currently targets the underlying cause of RRP.

The European filing represents the company’s next regulatory step toward expanding sales of VOCERYQ, previously known as INO-3107, while its U.S. commercialization remains in the initial stages.

READ:  Strainsert Reports Sensor Warranty Returns Below 0.5%

INOVIO expects the treatment to become available for ordering and shipment in the United States approximately 60 days after FDA approval, with a full commercial launch planned for the first quarter of 2027.

VOCERYQ is designed to stimulate an immune response against HPV-6 and HPV-11 antigens, potentially reducing the frequency of surgeries needed to remove recurring papillomas.

The disease can cause breathing complications, airway obstruction and impaired speech. Although the growths are generally benign, they frequently recur after surgical removal, requiring repeated procedures that can damage the vocal cords.

“Every surgery matters, because every surgery puts a patient’s vocal cords at risk,” said Frederik Dikkers, professor emeritus of otorhinolaryngology and head and neck surgery at Amsterdam University Medical Center.

The FDA granted accelerated approval based on evidence that VOCERYQ reduced the frequency of surgical papilloma excisions. Continued U.S. authorization may depend on confirmatory studies verifying and further characterizing its clinical benefit.

READ:  Toppoint Plans Reverse Split After NYSE American Trading Halt

The European application is supported by preclinical, clinical and manufacturing information, including results published in Nature Communications and The Laryngoscope in 2025.

Additional findings examining long-term efficacy and immune responses were published in The Laryngoscope in October 2026.

INOVIO is seeking conditional marketing authorization, a European regulatory pathway that can permit earlier access to medicines addressing unmet medical needs while additional evidence is collected.

The European Commission granted the treatment orphan drug designation in 2023, recognizing its development for a rare condition.

The EMA’s Committee for Advanced Therapies also previously certified the product’s chemistry, manufacturing, controls and nonclinical data against standards used in European marketing authorization assessments.

That certification supports the regulatory submission but does not constitute approval of the treatment.

INOVIO prepared the application following consultations with the EMA and its designated rapporteurs.

The company administers VOCERYQ using its CELLECTRA 5PSP delivery device, which already carries a CE mark permitting commercialization of the device in the European Union and other markets recognizing the designation.

READ:  Newrez Taps Former Rocket Executive to Lead $879 Billion Portfolio

The CE mark applies to the delivery device and does not independently authorize European sales of VOCERYQ.

Treatment involves surgical removal of visible papillomas before the first administration, followed by a nine-week dosing regimen that does not require additional surgery as part of the scheduled treatment protocol.

INOVIO estimates that at least 25,000 people in the United States have RRP, based on its ongoing analysis of insurance claims data, with additional cases diagnosed annually.

The company has not provided a corresponding European patient estimate in its announcement.

European authorization would establish another potential market for VOCERYQ as INOVIO transitions from clinical development toward commercial operations.

The company has not specified when it expects an EMA decision.

Additional information about VOCERYQ is available at www.voceryq.com.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.